Pediatric Neuroblastoma Treatment Market

Report Overview

The global pediatric neuroblastoma treatment market was pegged at US$ 759.5 million in 2020 and is expected to witness a CAGR of 8.5% during the forecast period.

Market Fundamentals

Neuroblastoma is a cancerous tumor that begins in the nerve tissue of infants and very young children. It is the most common extracranial solid tumor of infancy. It is an embryonal malignancy of the sympathetic nervous system arising from neuroblasts (pluripotent sympathetic cells). Infants usually develop a form of neuroblastoma that is less aggressive and can mature into benign tumors.  Children over 12 to 18 months usually develop a more aggressive form of neuroblastoma that often invades vital structures and may spread throughout the body. The majority of cases affect young children before school age, with some cases beginning before birth and unusual cases first arising as late as adolescence.

[79454324]

Market Dynamics

The global pediatric neuroblastoma treatment market is mainly driven by the rising prevalence of neuroblastoma worldwide, strong product pipeline, increasing awareness programs, and growing public and private funding for R&D activities. Furthermore, growing collaboration among the prominent players and various organizations for R&D activities is also likely to play a pivotal role in contributing to the growth of the market globally. However, the high cost of the therapy and the adverse effects related to treatment are likely to restrain the market growth to a certain extent.

Market Ecosystem

The global pediatric neuroblastoma treatment market has been analyzed from four perspectives: Treatment Type, Risk Group, End User, and Region.

Pediatric Neuroblastoma Treatment Market by Treatment Type

Based on treatment type, the pediatric neuroblastoma treatment market has been segmented into chemotherapy, immunotherapy, targeted therapy, radiation therapy, and others (hormonal therapy, stem cell transplants, targeted therapy, etc.). The chemotherapy segment dominated the market with the largest share in 2020. The large share of the chemotherapy segment is attributed to the fact that it is the most common form of treatment prescribed for neuroblastoma. It can also be used before surgery to shrink the tumor or after surgery to destroy any remaining cancer cells.

Pediatric Neuroblastoma Treatment Market by Risk Group

[73452424]

Based on risk group, the pediatric neuroblastoma treatment market has been segmented into low risk, intermediate-risk, and high risk. The high risk segment dominated the market with the largest share in 2020, owing to the high prevalence rate of neuroblastoma in this segment. High-risk neuroblastoma accounts for approximately 70% of total neuroblastoma cases.

Pediatric Neuroblastoma Treatment Market by End User

Based on end-user, the pediatric neuroblastoma treatment market has been segmented into hospitals, cancer specialty centers, and others (ambulatory care centers, clinics, etc.). The hospital segment dominated the market with the largest share in 2020. The large share of this segment can be attributed to the high volume of pediatric patients visiting hospitals for diagnosis and treatment of neuroblastoma.

Pediatric Neuroblastoma Treatment Market by Region

Based on region, the global pediatric neuroblastoma treatment market has been segmented into North America, Europe, Asia Pacific, and the Rest of the World (ROW). North America dominated the pediatric neuroblastoma treatment market, followed by the Asia Pacific. The large share of North America in the global market can largely be attributed to advanced healthcare infrastructure, rising prevalence of pediatric neuroblastoma, and relatively high volume of pediatric patients at the hospitals admitted for the treatment of neuroblastoma.

Competitive Landscape

Some of the prominent players operating in the pediatric neuroblastoma treatment market includes:-

• Bayer AG
• Pfizer Inc
• Apeiron Biologics AG
• United Therapeutics Corporation
• Y-mAbs Therapeutics, Inc
• Cellectar Biosciences, Inc
• Clarity Pharmaceuticals
• Provectus Biopharmaceuticals, Inc
• Scorpion Therapeutics, among others

Strategic Developments

• In November 2020, Children's Hospital of Pennsylvania (CHOP) and Gustave Roussy, a cancer research organization based in France, received a $1.3 million grant from neuroblastoma clinical research charities to develop precision medicine treatments for pediatric cancer
• In June 2020, Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, received FDA approval for Rare Pediatric Disease Designation (RPDD) to 67Cu-SARTATE, a therapy for the clinical management of neuroblastoma.
• In November 2018, Provectus received orphan drug designation (ODD) by the FDA for its small molecule oncolytic immunotherapy PV-10 for the treatment of neuroblastoma
• In March 2018, Cellectar Biosciences received Orphan Drug Designation for CLR 131 from the FDA. CLR 131 is the company's lead Phospholipid Drug Conjugate (PDC) product candidate for the treatment of neuroblastoma

Frequently Asked Questions About This Report